NCT06515418 - Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

February 6, 2025

Study Completion Date

February 12, 2025

Conditions

Obesity

Interventions

DRUG

Oral Azelaprag (BGE-105)

Capsules

DRUG

Oral Placebo for Azelaprag (BGE-105)

Capsules

DRUG

Tirzepatide

Subcutaneous Injection

DRUG

Tirzepatide Placebo

Subcutaneous Injection

Trial Locations (14)

40213

Site 100, Louisville

44122

Site 108, Beachwood

48098

Site 111, Troy

58104

Site 109, Fargo

59701

Site 106, Butte

63303

Site 113, City of Saint Peters

70072

Site 101, Marrero

75230

Site 102, Dallas

84790

Site 104, St. George

85210

Site 110, Mesa

90057

Site 107, Los Angeles

91763

Site 103, Montclair

91978

Site 105, Spring Valley

02114

Site 112, Boston